Immunogenic chemotherapy: great potential for improving response rates.

Area of Science:

• Oncology
• Immunology
• Cancer Research

Background:

• Chemotherapy can activate anti-tumor immunity, potentially improving cancer treatment outcomes.
• Current chemotherapy use has limited success in achieving long-term survival or cure.
• The dose, schedule, and tumor model dependence of chemotherapy-induced immunity are often under-appreciated.

Purpose of the Study:

• To review the immune modulation functions of chemotherapy agents.
• To propose a model for chemotherapy-induced long-lasting anti-tumor responses.
• To identify needs for optimizing chemotherapy and combination therapies.

Main Methods:

• Review of chemotherapy agents' immune modulation functions.
• Analysis of chemotherapy treatment schedules and their impact on immunity.
• Examination of tumor cell intrinsic factors influencing chemotherapy efficacy.
• Review of biomarkers for treatment responsiveness.

Main Results:

• Chemotherapy can induce immunogenic cell death, stimulating anti-tumor immunity.
• Optimizing chemotherapy dose and schedule is crucial for effective anti-tumor responses.
• Combination therapy with immunotherapy may be necessary when immune response is low.
• Tumor cell factors influence optimal chemotherapy strategies.

Conclusions:

• A deeper understanding of chemotherapy-induced immunity is needed for better cancer treatments.
• Optimized chemotherapy and chemo-immunotherapy can improve patient survival and cure rates.
• Biomarkers are essential for monitoring and predicting treatment response.